XBIT241220P15000
- 0.00
- 0.000.00%
XBiotech Newsroom
XBiotech | 10-Q: Q3 2024 Earnings Report
XBiotech: Q2 Earnings Snapshot
XBiotech | 10-Q: Q2 2024 Earnings Report
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
XBiotech Shares Are Trading Higher After the Company Shared Results From the 1-BETTER Study for Advanced Pancreatic Cancer.
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
XBiotech Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech | 10-Q: Q1 2024 Earnings Report
XBiotech Inc.'s (NASDAQ:XBIT) Market Cap up US$57m Last Week, Benefiting Both Retail Investors Who Own 45% as Well as Insiders
XBiotech Inc.'s (NASDAQ:XBIT) Top Owners Are Retail Investors With 44% Stake, While 44% Is Held by Insiders
12 Health Care Stocks Moving In Monday's Pre-Market Session
XBiotech to Begin Constructing New R&D Facility on Its 48-acre Campus
ARCT, EHTH and CRTO Are Among After Hour Movers
Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth
Press Release: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Individual Investors Account for 50% of XBiotech Inc.'s (NASDAQ:XBIT) Ownership, While Insiders Account for 35%
12 Health Care Stocks Moving In Tuesday's After-Market Session
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer